SUBSCRIBE
SUBSCRIBE

Phase III

Drug Development
How A Celgene-Partnered Drug Trial Could Save Struggling Acceleron Pharma
June 14, 2017
 · 
1 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
Why Celgene Gets No R-E-S-P-E-C-T, But Should
June 13, 2017
 · 
2 min read
Merck & Co.'s Alzheimer's Contender Wows in Human Clinical Trial
Drug Development
Deaths Force Merck & Co. to Halt Enrollment for Blood Cancer Studies
June 13, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
SoCal’s Regulus Sinks After AstraZeneca PLC Bails on Lead NASH Drug
June 12, 2017
 · 
3 min read
Tiny Bay Area Biotech Wants to Rattle the Billion-Dollar Injectable Drug Markets With a Single Pill
Drug Development
Tiny Bay Area Biotech Wants to Rattle the Billion-Dollar Injectable Drug Markets With a Single Pill
June 8, 2017
 · 
2 min read
Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Drug Development
Bristol-Myers Squibb Loses $4.3 Billion in Market Value After ASCO Update
June 7, 2017
 · 
3 min read
Drug Development
Why Johnson & Johnson’s New Prostate Cancer Drug Could Spell Trouble For Pfizer
June 7, 2017
 · 
1 min read
Genentech Grows on Promise of 70+ Drug Approvals
Drug Development
Genentech’s Perjeta-Based Adjuvant Breast Cancer Care Shows Minor Improvement, Puma Biotech Shares Jump
June 6, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
Acorda Jumps as Parkinson’s Drug Performs Well in Late-Stage Study
June 6, 2017
 · 
2 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Drug Development
Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It
June 5, 2017
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
January 28, 2026
 · 
4 min read
Press Releases
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
January 28, 2026
 · 
7 min read
Press Releases
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
January 28, 2026
 · 
6 min read
Load More